# Lewis J Rubin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11324670/publications.pdf

Version: 2024-02-01

| 254 | 48,712 | 3334 91 | 1536 218 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 265 | 265 | 265 | 15456 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. Advances in Therapy, 2022, 39, 796-810. | 2.9 | 12 |
| 2 | The physiological basis of pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2102334. | 6.7 | 61 |
| 3 | The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the <scp>GRIPHON</scp> study. European Journal of Heart Failure, 2022, 24, 205-214. | 7.1 | 22 |
| 4 | Comparative bioavailability of inhaled treprostinil administered as LIQ861 and TyvasoÂ® in healthy subjects. Vascular Pharmacology, 2021, 138, 106840. | 2.1 | 4 |
| 5 | Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. Chest, 2021, 160, 277-286. | 0.8 | 21 |
| 6 | Itâ€™s Time to Put the Term â€œPulmonary Vasodilatorsâ€•to Rest. JACC Basic To Translational Science, 2021, 6, 870-871. | 4.1 | 1 |
| 7 | Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. Journal of Heart and Lung Transplantation, 2020, 39, 300-309. | 0.6 | 39 |
| 8 | Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). JACC: Cardiovascular Interventions, 2020, 13, 989-999. | 2.9 | 47 |
| 9 | Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 1286-1295. | 0.6 | 62 |
| 10 | Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095. | 2.2 | 8 |
| 11 | Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. Circulation, 2019, 139, 2440-2450. | 1.6 | 67 |
| 12 | Initial combination therapy with ambrisentanâ€¯+â€¯tadalafil on pulmonary arterial hypertensionâ€'related hospitalization in the AMBITION trial. Journal of Heart and Lung Transplantation, 2019, 38, 194-202. | 0.6 | 19 |
| 13 | Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure, 2019, 21, 352-359. | 7.1 | 40 |
| 14 | Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908. | 6.7 | 142 |
| 15 | An overview of the 6th World Symposium on Pulmonary Hypertension. European Respiratory Journal, 2019, 53, 1802148. | 6.7 | 345 |
| 16 | Cor Pulmonale Revisited. From Ferrer and Harvey to the Present. Annals of the American Thoracic Society, 2018, 15, S42-S44. | 3.2 | 8 |
| 17 | Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763. | 2.8 | 82 |
| 18 | Assessing Prognosis of Pulmonary Arterial Hypertension in the Therapeutic Era. Circulation, 2018, 137, 705-706. | 1.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Macitentan in pulmonary hypertension due to left ventricular dysfunction. European Respiratory Journal, 2018, 51, 1701886. | 6.7 | 139 |
| 20 | Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. American Journal of Cardiovascular Drugs, 2018, 18, 37-47. | 2.2 | 69 |
| 21 | Overdue to understand anticoagulation in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-1. | 1.7 | 1 |
| 22 | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. Journal of Heart and Lung Transplantation, 2018, 37, 401-408. | 0.6 | 15 |
| 23 | Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. Journal of Heart and Lung Transplantation, 2018, 37, 1410-1417. | 0.6 | 15 |
| 24 | Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226. | 2.5 | 33 |
| 25 | Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519. | 0.6 | 22 |
| 26 | Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227. | 0.9 | 135 |
| 27 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1602493. | 6.7 | 97 |
| 28 | Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118. | 0.8 | 46 |
| 29 | SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155. | 2.2 | 65 |
| 30 | Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. European Respiratory Review, 2017, 26, 170094. | 7.1 | 60 |
| 31 | Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System. Chest, 2016, 150, 27-34. | 0.8 | 48 |
| 32 | Are Animal Models in PulmonaryÂHypertension Relevant toÂtheÂClinicalÂDisease? â^—. Journal of the American College of Cardiology, 2016, 67, 2047-2049. | 2.8 | 3 |
| 33 | Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respiratory Medicine,the, 2016, 4, 894-901. | 10.7 | 59 |
| 34 | Pulmonary Hypertension OverlapÂSyndromes. Journal of the American College of Cardiology, 2016, 68, 379-381. | 2.8 | 5 |
| 35 | Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720. | 6.7 | 39 |
| 36 | Pulmonary Artery Denervation for Pulmonary Artery Hypertension. JACC: Cardiovascular Interventions, 2015, 8, 2024-2025. | 2.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533. | 27.0 | 790 |
| 38 | Improving patient outcomes in pulmonary hypertension. European Respiratory Review, 2015, 24, 550-551. | 7.1 | 5 |
| 39 | Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313. | 6.7 | 174 |
| 40 | The Beta-Adrenergic Receptor in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2015, 65, 681-683. | 2.8 | 12 |
| 41 | Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347. | 0.6 | 10 |
| 42 | Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning. European Respiratory Journal, 2015, 46, 297-298. | 6.7 | 4 |
| 43 | Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 834-844. | 27.0 | 906 |
| 44 | Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8. | 4.1 | 51 |
| 45 | New horizons in pulmonary arterial hypertension management. European Respiratory Review, 2014, 23, 408-409. | 7.1 | 3 |
| 46 | Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2014, 33, 689-697. | 0.6 | 23 |
| 47 | Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. American Heart Journal, 2014, 167, 218-225.e1. | 2.7 | 27 |
| 48 | Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. International Journal of Cardiology, 2014, 172, 332-339. | 1.7 | 47 |
| 49 | Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Safety, 2014, 13, 391-405. | 2.4 | 60 |
| 50 | Chronic thromboembolic pulmonary hypertension. Lancet Respiratory Medicine,the, 2014, 2, 573-582. | 10.7 | 146 |
| 51 | Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340. | 27.0 | 1,120 |
| 52 | Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818. | 27.0 | 1,168 |
| 53 | Updated Treatment Algorithm of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D60-D72. | 2.8 | 596 |
| 54 | New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. Journal of the American College of Cardiology, 2013, 62, D82-D91. | 2.8 | 113 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Riociguat for Pulmonary Hypertension. New England Journal of Medicine, 2013, 369, 2266-2268. | 27.0 | 21 |
| 56 | Cor Pulmonale Revisited. Journal of the American College of Cardiology, 2013, 62, 1112-1113. | 2.8 | 12 |
| 57 | Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Cardiovascular Therapeutics, 2013, 31, 38-44. | 2.5 | 29 |
| 58 | Treprostinil for the treatment of pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2013, 11, 13-25. | 1.5 | 25 |
| 59 | Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The) Tj ETQq1 1 0.784314 rgBT /Overlock | 6.8 | 276 |
| 60 | Treatment of Pulmonary Hypertension Caused by Left Heart Failure With Pulmonary Arterial Hypertensionâ€“Specific Therapies. Circulation, 2013, 128, 475-476. | 1.6 | 6 |
| 61 | Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2013, 127, 624-633. | 1.6 | 291 |
| 62 | A paradigm shift in pulmonary arterial hypertension management. European Respiratory Review, 2013, 22, 423-426. | 7.1 | 3 |
| 63 | Contemporary Trends in the Diagnosis and Management of Pulmonary Arterial Hypertension. Chest, 2013, 143, 324-332. | 0.8 | 122 |
| 64 | Pulmonary Hypertension: Current Management and Future Directions. Handbook of Experimental Pharmacology, 2013, 218, 551-555. | 1.8 | 1 |
| 65 | Pulmonary Hypertension: Current Management and Future Directions. Handbook of Experimental Pharmacology, 2013, , 551-555. | 1.8 | 1 |
| 66 | Exercise training for pulmonary hypertension: another prescription to write?. European Respiratory Journal, 2012, 40, 7-8. | 6.7 | 10 |
| 67 | Safety and efficacy evaluation of ambrisentan in pulmonary hypertension. Expert Opinion on Drug Safety, 2012, 11, 1003-1011. | 2.4 | 19 |
| 68 | Future Perspectives in Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 276-279. | 0.1 | 1 |
| 69 | ARIESâ€3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Cardiovascular Therapeutics, 2012, 30, 93-99. | 2.5 | 85 |
| 70 | The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Annals of the Rheumatic Diseases, 2012, 71, 249-252. | 0.9 | 63 |
| 71 | Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 1546-1550. | 1.6 | 34 |
| 72 | Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sciences, 2012, 91, 517-521. | 4.3 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?. Life Sciences, 2012, 91, 528-539. | 4.3 | 76 |
| 74 | The study of risk in pulmonary arterial hypertension. European Respiratory Review, 2012, 21, 234-238. | 7.1 | 15 |
| 75 | The 6-Minute Walk Test in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 396-397. | 5.6 | 25 |
| 76 | Inhaled treprostinil: a therapeutic review. Drug Design, Development and Therapy, 2012, 6, 19. | 4.3 | 43 |
| 77 | Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research and Therapy, 2011, 13, 114. | 3.5 | 8 |
| 78 | Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation, 2011, 30, 1327-1333. | 0.6 | 98 |
| 79 | Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 2011, 38, 2419-2427. | 2.0 | 4 |
| 80 | Combination Therapy for Pulmonary Artery Hypertension: What Is the Evidence?. Cardiology, 2011, 120, 172-173. | 1.4 | 3 |
| 81 | Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension. Chest, 2011, 140, 1274-1283. | 0.8 | 237 |
| 82 | Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. Annals of the Rheumatic Diseases, 2010, 69, 1360-1363. | 0.9 | 34 |
| 83 | Echocardiography as an Outcome Measure in Scleroderma-related Pulmonary Arterial Hypertension: A Systematic Literature Analysis by the EPOSS Group. Journal of Rheumatology, 2010, 37, 105-115. | 2.0 | 37 |
| 84 | Worldwide Physician Education and Training in Pulmonary Hypertension. Chest, 2010, 137, 85S-94S. | 0.8 | 26 |
| 85 | Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 55, 1915-1922. | 2.8 | 484 |
| 86 | Editor's response to â€œEthical issues associated with globalization of placebo-controlled trials in pulmonary arterial hypertensionâ€. Journal of Heart and Lung Transplantation, 2010, 29, 827-828. | 0.6 | 1 |
| 87 | Metabolic Dysfunction in the Pathogenesis of Pulmonary Hypertension. Cell Metabolism, 2010, 12, 313-314. | 16.2 | 9 |
| 88 | Pulmonary Vasodilators in COPD. , 2009, , 699-704. | | 0 |
| 89 | ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Circulation, 2009, 119, 2250-2294. | 1.6 | 992 |
| 90 | Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 881-886. | 5.6 | 141 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Medical Treatment of Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 484-492. | 2.1 | 6 |
| 92 | A Functional Single-Nucleotide Polymorphism in theTRPC6Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension. Circulation, 2009, 119, 2313-2322. | 1.6 | 173 |
| 93 | Identification of putative endothelial progenitor cells (CD34<sup>+</sup>CD133<sup>+</sup>Flk-1<sup>+</sup>) in endarterectomized tissue of patients with chronic thromboembolic pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 296, L870-L878. | 2.9 | 77 |
| 94 | Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol. Journal of Rheumatology, 2009, 36, 2244-2249. | 2.0 | 77 |
| 95 | Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2009, 22, 50-56. | 2.6 | 43 |
| 96 | ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 53, 1573-1619. | 2.8 | 1,797 |
| 97 | Endothelin and the Systemic Circulation. Journal of the American College of Cardiology, 2009, 53, 1318-1319. | 2.8 | 2 |
| 98 | Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S108-S117. | 2.8 | 62 |
| 99 | Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S78-S84. | 2.8 | 463 |
| 100 | Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, 1971-1981. | 2.8 | 227 |
| 101 | Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. Chest, 2009, 135, 122-129. | 0.8 | 167 |
| 102 | Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension. Chest, 2009, 135, 130-136. | 0.8 | 49 |
| 103 | Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. Arthritis and Rheumatism, 2008, 59, 867-875. | 6.7 | 56 |
| 104 | Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2008, 51, 1527-1538. | 2.8 | 269 |
| 105 | Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology, 2008, 52, 2127-2134. | 2.8 | 506 |
| 106 | Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 824-832. | 2.6 | 64 |
| 107 | Treatment of Pulmonary Arterial Hypertension Due to Scleroderma: Challenges for the Future. Rheumatic Disease Clinics of North America, 2008, 34, 191-197. | 1.9 | 7 |
| 108 | Exercise-Induced Pulmonary Arterial Hypertension. Circulation, 2008, 118, 2120-2121. | 1.6 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Pulmonary Arterial Hypertension. , 2008, , 759-771. | | 0 |
| 110 | Prednisolone inhibits PDGF-induced nuclear translocation of NF-Î²B in human pulmonary artery smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L648-L657. | 2.9 | 28 |
| 111 | Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3010-3019. | 1.6 | 967 |
| 112 | BMPR2 Mutation and Outcome in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1300-1301. | 5.6 | 7 |
| 113 | Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2008, 149, 521. | 3.9 | 558 |
| 114 | Upregulation of Na+/Ca2+ exchanger contributes to the enhanced Ca2+ entry in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. American Journal of Physiology - Cell Physiology, 2007, 292, C2297-C2305. | 4.6 | 79 |
| 115 | Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1272-1279. | 5.6 | 227 |
| 116 | Function of Kv1.5 channels and genetic variations ofKCNA5in patients with idiopathic pulmonary arterial hypertension. American Journal of Physiology - Cell Physiology, 2007, 292, C1837-C1853. | 4.6 | 141 |
| 117 | Central Venous Blood Oxygen Saturation Monitoring in Patients With Chronic Pulmonary Arterial Hypertension Treated With Continuous IV Epoprostenol. Chest, 2007, 132, 786-792. | 0.8 | 10 |
| 118 | Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease. Arthritis Research and Therapy, 2007, 9, S10. | 3.5 | 3 |
| 119 | Medical Therapy for Pulmonary Arterial Hypertension. Chest, 2007, 131, 1917-1928. | 0.8 | 477 |
| 120 | Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. Journal of Rheumatology, 2007, 34, 2417-22. | 2.0 | 152 |
| 121 | Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 48, 1433-1437. | 2.8 | 115 |
| 122 | Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology, 2006, 48, 1672-1681. | 2.8 | 135 |
| 123 | Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology, 2006, 48, 2546-2552. | 2.8 | 498 |
| 124 | Temporal trends and drug exposures in pulmonary hypertension: An American experience. American Heart Journal, 2006, 152, 521-526. | 2.7 | 78 |
| 125 | ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2006, 130, 121S. | 0.8 | 27 |
| 126 | Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?. Chest, 2006, 130, 1657-1663. | 0.8 | 173 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Update in Pulmonary Hypertension 2005. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 499-505. | 5.6 | 40 |
| 128 | Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1257-1263. | 5.6 | 565 |
| 129 | Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2006, 113, 2011-2020. | 1.6 | 791 |
| 130 | Pulmonary Arterial Hypertension. Proceedings of the American Thoracic Society, 2006, 3, 111-115. | 3.5 | 80 |
| 131 | Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses. Proceedings of the American Thoracic Society, 2006, 3, 601-607. | 3.5 | 48 |
| 132 | Endothelin-1 and the Pulmonary Vascular Response to Altitude. Circulation, 2006, 114, 1350-1351. | 1.6 | 21 |
| 133 | Thyrotoxicosis as a Risk Factor for Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 222. | 3.9 | 1 |
| 134 | Management following pulmonary thromboendarterectomy: Experience versus evidence*. Critical Care Medicine, 2005, 33, 2132-2133. | 0.9 | 2 |
| 135 | The right ventricle in pulmonary hypertension. Coronary Artery Disease, 2005, 16, 13-18. | 0.7 | 373 |
| 136 | Ambrisentan for pulmonary arterial hypertension. Future Cardiology, 2005, 1, 425-432. | 1.2 | 17 |
| 137 | Pathogenesis of Pulmonary Arterial Hypertension. Circulation, 2005, 111, 534-538. | 1.6 | 186 |
| 138 | Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2005, 6, 1921-1930. | 1.8 | 18 |
| 139 | Evaluation and Management of the Patient with Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2005, 143, 282. | 3.9 | 121 |
| 140 | Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2005, 353, 2148-2157. | 27.0 | 2,237 |
| 141 | Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 529-535. | 2.8 | 441 |
| 142 | Bosentan Inhibits Transient Receptor Potential Channel Expression in Pulmonary Vascular Myocytes. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1101-1107. | 5.6 | 91 |
| 143 | Preoperative Partitioning of Pulmonary Vascular Resistance Correlates With Early Outcome After Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2004, 109, 18-22. | 1.6 | 377 |
| 144 | Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13861-13866. | 7.1 | 395 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278. | 2.2 | 903 |
| 146 | Pulmonary arterial hypertension: a look to the future. Journal of the American College of Cardiology, 2004, 43, S89-S90. | 2.8 | 34 |
| 147 | Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12. | 2.8 | 1,542 |
| 148 | Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S81-S88. | 2.8 | 206 |
| 149 | Endothelin receptor antagonists in pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S62-S67. | 2.8 | 153 |
| 150 | Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvascular Research, 2004, 68, 75-103. | 2.5 | 263 |
| 151 | Introduction. Chest, 2004, 126, 7S-10S. | 0.8 | 244 |
| 152 | Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Chest, 2004, 126, 420-427. | 0.8 | 232 |
| 153 | Executive Summary. Chest, 2004, 126, 4S-6S. | 0.8 | 60 |
| 154 | Bosentan: profile report. Drugs and Therapy Perspectives, 2003, 19, 5-6. | 0.6 | 0 |
| 155 | Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension. Chest, 2003, 124, 247-254. | 0.8 | 271 |
| 156 | Successful Withdrawal of Long-term Epoprostenol Therapy for Pulmonary Arterial Hypertension. Chest, 2003, 124, 1612-1615. | 0.8 | 43 |
| 157 | Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension. Journal of Cardiovascular Pharmacology, 2003, 41, 293-299. | 1.9 | 219 |
| 158 | Epoprostenol Therapy as a Bridge to Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension. Chest, 2003, 123, 319-320. | 0.8 | 32 |
| 159 | High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2003, 90, 372-376. | 3.4 | 221 |
| 160 | Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L740-L754. | 2.9 | 237 |
| 161 | Bosentan: a dual endothelin receptor antagonist. Expert Opinion on Investigational Drugs, 2002, 11, 991-1002. | 4.1 | 65 |
| 162 | Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329. | 27.0 | 1,626 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | New Treatments for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1209-1216. | 5.6 | 129 |
| 164 | Differential Effects of Stable Prostacyclin Analogs on Smooth Muscle Proliferation and Cyclic AMP Generation in Human Pulmonary Artery. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 194-201. | 2.9 | 211 |
| 165 | Therapy of Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1308-1309. | 5.6 | 57 |
| 166 | Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension. Journal of Cardiovascular Pharmacology and Therapeutics, 2002, 7, 9-19. | 2.0 | 41 |
| 167 | Bosentan Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine, 2002, 346, 896-903. | 27.0 | 2,545 |
| 168 | Bosentan. American Journal of Cardiovascular Drugs, 2002, 2, 343. | 2.2 | 1 |
| 169 | Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research, 2002, 63, 227-246. | 1.2 | 32 |
| 170 | Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 800-804. | 5.6 | 1,288 |
| 171 | Chronic thromboembolic pulmonary hypertension. Progress in Cardiovascular Diseases, 2002, 45, 203-212. | 3.1 | 14 |
| 172 | Pulmonary Vasodilators. , 2002, , 605-609. | | 0 |
| 173 | Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet, The, 2001, 358, 1119-1123. | 13.7 | 1,421 |
| 174 | CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 561-581. | 2.1 | 102 |
| 175 | NEW AND EXPERIMENTAL THERAPIES FOR PULMONARY HYPERTENSION. Clinics in Chest Medicine, 2001, 22, 539-545. | 2.1 | 22 |
| 176 | UpregulatedTRPand enhanced capacitative Ca<sup>2+</sup>entry in human pulmonary artery myocytes during proliferation. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H746-H755. | 3.2 | 316 |
| 177 | Capacitative Ca<sup>2+</sup>entry in agonist-induced pulmonary vasoconstriction. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L870-L880. | 2.9 | 134 |
| 178 | Augmented K<sup>+</sup>currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L887-L894. | 2.9 | 79 |
| 179 | Chronic hypoxia decreases K<sub>V</sub>channel expression and function in pulmonary artery myocytes. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L801-L812. | 2.9 | 159 |
| 180 | c-Jun Decreases Voltage-Gated K + Channel Activity in Pulmonary Artery Smooth Muscle Cells. Circulation, 2001, 104, 1557-1563. | 1.6 | 43 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Increased Levels of Prostaglandin D2 Suggest Macrophage Activation in Patients With Primary Pulmonary Hypertension. Chest, 2001, 120, 1639-1644. | 0.8 | 26 |
| 182 | Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine, 2001, 345, 1465-1472. | 27.0 | 676 |
| 183 | Inhibition of K+ Channel Activity in Human Pulmonary Artery Smooth Muscle Cells by Serum from Patients with Pulmonary Hypertension Secondary to Congenital Heart Disease. Pediatric Research, 2001, 50, 23-28. | 2.3 | 9 |
| 184 | Altered Expression and Function of Kv Channels in Primary Pulmonary Hypertension. , 2001, , 821-836. | | 1 |
| 185 | Therapy of pulmonary hypertension: Targeting pathogenic mechanisms with selective treatment delivery. Critical Care Medicine, 2001, 29, 1086-1087. | 0.9 | 8 |
| 186 | Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. Annals of Internal Medicine, 2000, 132, 425. | 3.9 | 905 |
| 187 | Recreational Use of Aminorex and Pulmonary Hypertension. Chest, 2000, 118, 1496-1497. | 0.8 | 38 |
| 188 | Mortality From Primary Pulmonary Hypertension in the United States, 1979â€“1996. Chest, 2000, 117, 796-800. | 0.8 | 50 |
| 189 | Approach to pulmonary hypertension. Current Rheumatology Reports, 2000, 2, 517-523. | 4.7 | 1 |
| 190 | Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. American Journal of Physiology - Cell Physiology, 2000, 279, C1540-C1549. | 4.6 | 145 |
| 191 | Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus. Chest, 2000, 117, 14-18. | 0.8 | 109 |
| 192 | IV Epoprostenol in Gaucher's Disease. Chest, 2000, 117, 1821. | 0.8 | 0 |
| 193 | Combination therapy for pulmonary hypertension: A glimpse into the future?. Critical Care Medicine, 2000, 28, 896-897. | 0.9 | 13 |
| 194 | Continuous Intravenous Epoprostenol Therapy for Pulmonary Hypertension in Gaucher's Disease. Chest, 1999, 116, 1127-1129. | 0.8 | 23 |
| 195 | Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatric Pulmonology, 1999, 27, 194-197. | 2.0 | 16 |
| 196 | Cellular and molecular mechanisms responsible for the pathogenesis of primary pulmonary hypertension. Pediatric Pulmonology, 1999, 27, 194-197. | 2.0 | 1 |
| 197 | PORTOPULMONARY HYPERTENSION AND THE LIVER TRANSPLANT CANDIDATE. Transplantation, 1999, 67, 1087-1093. | 1.0 | 122 |
| 198 | Short-term Outcome and Predictors of Adverse Events following Pulmonary Thromboendarterectomy. World Journal of Surgery, 1998, 22, 1029-1033. | 1.6 | 30 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Action of fenfluramine on voltage- gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet, The, 1998, 352, 290. | 13.7 | 37 |
| 200 | Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet, The, 1998, 351, 726-727. | 13.7 | 263 |
| 201 | Primary pulmonary hypertension. Lancet, The, 1998, 352, 719-725. | 13.7 | 505 |
| 202 | Roles of K<sup>+</sup>and Cl<sup>-</sup>Channels in Camp-Induced Pulmonary Vasodilation. Experimental Lung Research, 1998, 24, 71-83. | 1.2 | 17 |
| 203 | Dysfunctional Voltage-Gated K <sup>+</sup> Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension. Circulation, 1998, 98, 1400-1406. | 1.6 | 385 |
| 204 | Medical and Surgical Treatment Options for Pulmonary Hypertension. American Journal of the Medical Sciences, 1998, 315, 179-184. | 1.1 | 7 |
| 205 | Molecular basis and function of voltage-gated K<sup>+</sup>channels in pulmonary arterial smooth muscle cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 274, L621-L635. | 2.9 | 103 |
| 206 | Medical and Surgical Treatment Options for Pulmonary Hypertension. American Journal of the Medical Sciences, 1998, 315, 179-184. | 1.1 | 19 |
| 207 | SUCCESSFUL USE OF CHRONIC EPOPROSTENOL AS A BRIDGE TO LIVER TRANSPLANTATION IN SEVERE PORTOPULMONARY HYPERTENSION1. Transplantation, 1998, 65, 457-459. | 1.0 | 115 |
| 208 | Distinctive Clinical Features of Portopulmonary Hypertension. Chest, 1997, 112, 980-986. | 0.8 | 149 |
| 209 | Primary Pulmonary Hypertension. New England Journal of Medicine, 1997, 336, 111-117. | 27.0 | 1,294 |
| 210 | CONTINUOUS INTRAVENOUS INFUSION OF EPOPROSTENOL FOR THE TREATMENT OF PORTOPULMONARY HYPERTENSION1. Transplantation, 1997, 63, 604-606. | 1.0 | 208 |
| 211 | Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension. Circulation, 1997, 95, 1479-1486. | 1.6 | 271 |
| 212 | Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. Journal of Applied Physiology, 1996, 81, 2595-2603. | 2.5 | 31 |
| 213 | The Renin-Angiotensin System and the â€œLesser Circulationâ€• Chest, 1996, 110, 584-585. | 0.8 | 3 |
| 214 | A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. New England Journal of Medicine, 1996, 334, 296-301. | 27.0 | 2,529 |
| 215 | Pathology and pathophysiology of primary pulmonary hypertension. American Journal of Cardiology, 1995, 75, 51A-54A. | 1.6 | 85 |
| 216 | Different Vasoactive Mechanisms of Various Pulmonary Vasodilators-To the Editor. Chest, 1994, 105, 1920-1921. | 0.8 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Investigation and Management of Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1993, 148, 1414-1417. | 2.9 | 39 |
| 218 | Primary Pulmonary Hypertension. Chest, 1993, 104, 236-250. | 0.8 | 346 |
| 219 | The Sodium Gradient, Potassium Channels, and Regulation of Calcium in Pulmonary and Mesenteric Arterial Smooth Muscles: Effects of Hypoxia. , 1993, , 205-222. | | 1 |
| 220 | Primary Pulmonary Hypertension. Drugs, 1992, 43, 37-43. | 10.9 | 8 |
| 221 | Reversible pulmonary hypertension associated with anorexigen use. American Journal of Medicine, 1991, 91, 97-99. | 1.5 | 18 |
| 222 | Performance of new criteria for right ventricular hypertrophy and myocardial infarction in patients with pulmonary hypertension due to cor pulmonale and mitral stenosis. Journal of Electrocardiology, 1991, 24, 231-237. | 0.9 | 12 |
| 223 | Cardiovascular effects of pulmonary hypertension. Trends in Cardiovascular Medicine, 1991, 1, 65-69. | 4.9 | 3 |
| 224 | Indomethacin Prevents Ventilation-Induced Decreases in Pulmonary Vascular Resistance of the Middle Region in Fetal Lambs. Pediatric Research, 1991, 29, 449-454. | 2.3 | 14 |
| 225 | Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol). Annals of Internal Medicine, 1990, 112, 485. | 3.9 | 621 |
| 226 | Effects of Nitrendipine and Hypoxia on Pulmonary Vascular Resistance in Experimental Emphysema. The American Review of Respiratory Disease, 1990, 142, 625-630. | 2.9 | 3 |
| 227 | Effects of chronic anemic hypoxia on skeletal muscle mass, protein degradation, and oxygen utilization. Journal of Critical Care, 1990, 5, 10-19. | 2.2 | 0 |
| 228 | The Acute Administration of Vasodilators in Primary Pulmonary Hypertension: Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. The American Review of Respiratory Disease, 1989, 140, 1623-1630. | 2.9 | 177 |
| 229 | Approach to the Diagnosis and Treatment of Pulmonary Hypertension. Chest, 1989, 96, 659-664. | 0.8 | 14 |
| 230 | The Influence of the Transmembrane Sodium Gradient on the Responses of Pulmonary Arteries to Decreases in Oxygen Tension. The American Review of Respiratory Disease, 1989, 139, 933-939. | 2.9 | 20 |
| 231 | Effects of Interleukin-2 on Oxygen Delivery and Consumption in Patients with Advanced Malignancy. Chest, 1988, 94, 816-821. | 0.8 | 8 |
| 232 | Pulmonary Vascular Structural and Functional Changes in Papain-induced Emphysema in Dogs. The American Review of Respiratory Disease, 1987, 136, 704-709. | 2.9 | 12 |
| 233 | Prostacyclin and PGE1 Treatment of Pulmonary Hypertension. The American Review of Respiratory Disease, 1987, 136, 773-776. | 2.9 | 96 |
| 234 | Noninvasive Evaluation of Right Ventricular Function. Clinics in Chest Medicine, 1987, 8, 65-80. | 2.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Long-term Effects of Nitrendipine on Hemodynamics and Oxygen Transport in Patients with Cor Pulmonale. Chest, 1986, 89, 141-145. | 0.8 | 36 |
| 236 | Oxygen Therapy Titrated to Raise Mixed Venous Oxygen Content in COPD. Chest, 1986, 89, 343-347. | 0.8 | 2 |
| 237 | Primary Pulmonary Hypertension. Medicine (United States), 1986, 65, 56. | 1.0 | 91 |
| 238 | Nafazatrom (Bay G 6575) blunts canine hypoxic pulmonary vasoconstriction: Evidence for a prostaglandin-mediated mechanism. Prostaglandins, Leukotrienes, and Medicine, 1985, 18, 95-104. | 0.7 | 2 |
| 239 | Calcium Channel Blockers in Primary Pulmonary Hypertension. Chest, 1985, 88, 257S-260S. | 0.8 | 16 |
| 240 | A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. American Heart Journal, 1985, 110, 1200-1204. | 2.7 | 52 |
| 241 | Relation between mixed venous oxygen tension and pulmonary vascular tone during normoxic, hyperoxic and hypoxic ventilation in dogs. American Journal of Cardiology, 1984, 54, 1118-1123. | 1.6 | 25 |
| 242 | Gas exchange during dialysis. American Journal of Medicine, 1984, 77, 255-260. | 1.5 | 38 |
| 243 | Clinical Evaluation. , 1984, , 107-115. | | 0 |
| 244 | Therapy of Pulmonary Heart Disease. , 1984, , 325-353. | | 3 |
| 245 | Effects of oral hydralazine on gas exchange in patients with cor pulmonale. American Journal of Medicine, 1983, 75, 937-942. | 1.5 | 29 |
| 246 | High sodium bicarbonate and acetate hemodialysis: Double-blind crossover comparison of hemodynamic and ventilatory effects. Kidney International, 1983, 24, 240-245. | 5.2 | 62 |
| 247 | Independence of Oxygen Consumption and Systemic Oxygen Transport in Patients with Either Stable Pulmonary Hypertension or Refractory Left Ventricular Failure1â€“4. The American Review of Respiratory Disease, 1983, 128, 30-33. | 2.9 | 80 |
| 248 | Primary Pulmonary Hypertension: An Unusual Case Associated with Extrahepatic Portal Hypertension. Hepatology, 1983, 3, 588-592. | 7.3 | 48 |
| 249 | Cardiovascular Effects of Vasodilator Therapy for Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 1983, 4, 309-319. | 2.1 | 20 |
| 250 | Treatment of Primary Pulmonary Hypertension with Nifedipine. Annals of Internal Medicine, 1983, 99, 433. | 3.9 | 92 |
| 251 | Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. American Journal of Cardiology, 1981, 47, 116-122. | 1.6 | 105 |
| 252 | Influence of Prostaglandin Synthesis Inhibitors on Pulmonary Vasodilatory Effects of Hydralazine in Dogs with Hypoxic Pulmonary Vasoconstriction. Journal of Clinical Investigation, 1981, 67, 193-200. | 8.2 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Oral Hydralazine Therapy for Primary Pulmonary Hypertension. New England Journal of Medicine, 1980, 302, 69-73. | 27.0 | 256 |
| 254 | Primary pulmonary hypertension: new approaches to therapy. American Heart Journal, 1980, 100, 757-759. | 2.7 | 10 |